321 related articles for article (PubMed ID: 26694375)
1. Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia.
Oda Y; Kanahara N; Iyo M
Int J Mol Sci; 2015 Dec; 16(12):30144-63. PubMed ID: 26694375
[TBL] [Abstract][Full Text] [Related]
2. Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.
Nakata Y; Kanahara N; Iyo M
J Psychopharmacol; 2017 Dec; 31(12):1511-1518. PubMed ID: 28925317
[TBL] [Abstract][Full Text] [Related]
3. Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis.
Takase M; Kimura H; Kanahara N; Nakata Y; Iyo M
J Psychopharmacol; 2020 May; 34(5):540-547. PubMed ID: 31961236
[TBL] [Abstract][Full Text] [Related]
4. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.
Kimura H; Kanahara N; Sasaki T; Komatsu N; Ishige M; Muneoka K; Ino H; Yoshimura K; Yamanaka H; Suzuki T; Komatsu H; Watanabe H; Shimizu E; Iyo M
J Psychopharmacol; 2016 Aug; 30(8):795-802. PubMed ID: 27371496
[TBL] [Abstract][Full Text] [Related]
5. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis.
Iyo M; Tadokoro S; Kanahara N; Hashimoto T; Niitsu T; Watanabe H; Hashimoto K
J Clin Psychopharmacol; 2013 Jun; 33(3):398-404. PubMed ID: 23609386
[TBL] [Abstract][Full Text] [Related]
6. Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats.
Oda Y; Fujita Y; Oishi K; Nakata Y; Takase M; Niitsu T; Kanahara N; Shirayama Y; Hashimoto K; Iyo M
Psychopharmacology (Berl); 2017 Oct; 234(20):3027-3036. PubMed ID: 28744562
[TBL] [Abstract][Full Text] [Related]
7. Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia.
Kanahara N; Kimura H; Oda Y; Ito F; Iyo M
Curr Neuropharmacol; 2021; 19(12):2214-2226. PubMed ID: 33550976
[TBL] [Abstract][Full Text] [Related]
8. Genetic association between G protein-coupled receptor kinase 6/β-arrestin 2 and dopamine supersensitivity psychosis in schizophrenia.
Oda Y; Kanahara N; Kimura H; Watanabe H; Hashimoto K; Iyo M
Neuropsychiatr Dis Treat; 2015; 11():1845-51. PubMed ID: 26251601
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.
Chouinard G; Samaha AN; Chouinard VA; Peretti CS; Kanahara N; Takase M; Iyo M
Psychother Psychosom; 2017; 86(4):189-219. PubMed ID: 28647739
[TBL] [Abstract][Full Text] [Related]
10. G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis.
Oda Y; Tadokoro S; Takase M; Kanahara N; Watanabe H; Shirayama Y; Hashimoto K; Iyo M
J Psychopharmacol; 2015 Dec; 29(12):1308-13. PubMed ID: 26174132
[TBL] [Abstract][Full Text] [Related]
11. Effects of repeated electroconvulsive shocks on dopamine supersensitivity psychosis model rats.
Kimura M; Oda Y; Oishi K; Yoshino K; Kimura H; Niitsu T; Kanahara N; Shirayama Y; Hashimoto K; Iyo M
Schizophr Res; 2021 Feb; 228():1-6. PubMed ID: 33429150
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study.
Kanahara N; Takase M; Sasaki T; Honma M; Fujita Y; Tadokoro S; Suzuki H; Yamanaka H; Noda S; Yanahashi S; Saiga T; Komatsu N; Simoyama T; Iyo M
Int Clin Psychopharmacol; 2020 Nov; 35(6):338-344. PubMed ID: 32868522
[TBL] [Abstract][Full Text] [Related]
13. Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia.
Suzuki T; Kanahara N; Yamanaka H; Takase M; Kimura H; Watanabe H; Iyo M
Psychiatry Res; 2015 Jun; 227(2-3):278-82. PubMed ID: 25863824
[TBL] [Abstract][Full Text] [Related]
14. Vulnerable combinations of functional dopaminergic polymorphisms to late-onset treatment resistant schizophrenia.
Oishi K; Kanahara N; Takase M; Oda Y; Nakata Y; Niitsu T; Ishikawa M; Sato Y; Iyo M
PLoS One; 2018; 13(11):e0207133. PubMed ID: 30408108
[TBL] [Abstract][Full Text] [Related]
15. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors.
Seeman P
CNS Neurosci Ther; 2011 Apr; 17(2):118-32. PubMed ID: 20560996
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review.
Yin J; Barr AM; Ramos-Miguel A; Procyshyn RM
Curr Neuropharmacol; 2017; 15(1):174-183. PubMed ID: 27264948
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Treatment With Long-Acting Injectable Antipsychotic in Schizophrenia Patients With and Without Dopamine Supersensitivity Psychosis: A 6-Year Retrospective Comparative Study.
Kogure M; Kanahara N; Kimura M; Hanaoka S; Hirano H; Iyo M
J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):357-364. PubMed ID: 35727084
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic-induced supersensitivity - A reappraisal.
Lugg W
Aust N Z J Psychiatry; 2022 May; 56(5):437-444. PubMed ID: 34144649
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic-evoked dopamine supersensitivity.
Servonnet A; Samaha AN
Neuropharmacology; 2020 Feb; 163():107630. PubMed ID: 31077727
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Asenapine in Drug-resistant Psychotic Patients with Dopamine Supersensitivity Psychosis: Two Cases.
Kanahara N; Kimura H; Kinoshita T; Iyo M; Takekita Y
Clin Psychopharmacol Neurosci; 2023 Feb; 21(1):197-201. PubMed ID: 36700326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
